WO2013090664A1 - Derivatives of betulin - Google Patents

Derivatives of betulin Download PDF

Info

Publication number
WO2013090664A1
WO2013090664A1 PCT/US2012/069637 US2012069637W WO2013090664A1 WO 2013090664 A1 WO2013090664 A1 WO 2013090664A1 US 2012069637 W US2012069637 W US 2012069637W WO 2013090664 A1 WO2013090664 A1 WO 2013090664A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
alkyl
oxo
process according
Prior art date
Application number
PCT/US2012/069637
Other languages
English (en)
French (fr)
Inventor
Mark Andrew HATCHER
Brian Alvin Johns
Michael Tolar Martin
Elie Amine TABET
Jun Tang
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020147019864A priority Critical patent/KR101953869B1/ko
Priority to MX2014007280A priority patent/MX360679B/es
Priority to LTEP12857774.9T priority patent/LT2791103T/lt
Priority to US14/365,802 priority patent/US20150218142A1/en
Priority to JP2014547462A priority patent/JP6300730B2/ja
Priority to SI201231079T priority patent/SI2791103T1/sl
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Priority to SG11201402707PA priority patent/SG11201402707PA/en
Priority to DK12857774.9T priority patent/DK2791103T3/en
Priority to CN201280069739.7A priority patent/CN105008322B/zh
Priority to BR112014014769-8A priority patent/BR112014014769A2/pt
Priority to UAA201406100A priority patent/UA116978C2/uk
Priority to AU2012352110A priority patent/AU2012352110B2/en
Priority to PL12857774T priority patent/PL2791103T3/pl
Priority to RS20170937A priority patent/RS56373B1/sr
Priority to CA2859030A priority patent/CA2859030C/en
Priority to EP12857774.9A priority patent/EP2791103B1/en
Priority to EA201490919A priority patent/EA027363B1/ru
Priority to ES12857774.9T priority patent/ES2644578T3/es
Priority to MEP-2017-198A priority patent/ME02895B/me
Priority to NZ625516A priority patent/NZ625516B2/en
Publication of WO2013090664A1 publication Critical patent/WO2013090664A1/en
Priority to ZA2014/04135A priority patent/ZA201404135B/en
Priority to IL233081A priority patent/IL233081A/en
Priority to MA37132A priority patent/MA35833B1/fr
Priority to PH12014501362A priority patent/PH12014501362A1/en
Priority to US14/757,754 priority patent/US20160120878A1/en
Priority to PH12017501426A priority patent/PH12017501426A1/en
Priority to PH12017501429A priority patent/PH12017501429A1/en
Priority to US15/685,150 priority patent/US20170348324A1/en
Priority to CY20171101043T priority patent/CY1119422T1/el
Priority to HRP20171512TT priority patent/HRP20171512T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/26—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings

Definitions

  • the present invention relates to compounds, pharmaceutical compositions, and methods of use thereof for (i) inhibiting HIV replication in a subject infected with HIV, or (ii) treating a subject infected with HIV, by administering such compounds.
  • HIV-1 Human immunodeficiency virus type 1
  • AIDS acquired immune deficiency disease
  • HAART highly active antiretroviral therapy
  • HAART therapies are often complex because a combination of different drugs must be administered often daily to the patient to avoid the rapid emergence of drug-resistant HIV-1 variants.
  • drug resistance can still occur.
  • the emergence of multidrug-resistant HIV-1 isolates has serious clinical consequences and must be suppressed with a new drug regimen, known as salvage therapy.
  • salvage therapy includes at least two, and preferably three, fully active drugs.
  • first-line therapies combine three to four drugs targeting the viral enzymes reverse transcriptase and protease.
  • One option for salvage therapy is to administer different combinations of drugs from the same mechanistic class that remain active against the resistant isolates.
  • HAART highly active antiretroviral therapy
  • the HIV Gag polyprotein precursor (Pr55Gag), which is composed of four protein domains - matrix (MA), capsid (CA), nucleocapsid (NC) and p6 - and two spacer peptides, SP1 and SP2, represents a new therapeutic target.
  • Pr55Gag The HIV Gag polyprotein precursor
  • MA protein domains - matrix
  • CA capsid
  • NC nucleocapsid
  • SP1 and SP2 two spacer peptides
  • MA domain of Gag mediates membrane binding. Assembly is completed by budding of the immature particle from the cell. Concomitant with particle release, the virally encoded PR cleaves Gag into the four mature protein domains, MA, CA, NC and p6, and the two spacer peptides, SP1 and SP2. Gag-Pol is also cleaved by PR, liberating the viral enzymes PR, RT and IN. Gag proteolytic processing induces a
  • Maturation converts the immature, donut-shaped particle to the mature virion, which contains a condensed conical core composed of a CA shell surrounding the viral RNA genome in a complex with NC and the viral enzymes RT and IN. Maturation prepares the virus for infection of a new cell and is absolutely essential for particle infectivity.
  • Bevirimat (PA-457) is a maturation inhibitor that inhibits the final step in the processing of Gag, the conversion of capsid-SP1 (p25) to capsid, which is required for the formation of infectious viral particles.
  • Bevirimat has activity against ART-resistant and wild-type HIV, and has shown synergy with antiretrovirals from all classes.
  • Bevirimat users with Gag polymorphisms at Q369, V370 or T371 demonstrated significantly lower load reductions than patients without Gag polymorphisms at these sites.
  • Maturation inhibitors in the prior art leave open gaps in the areas of polymorphism coverage whereby potency against a broad range of clinically relevant gag sequences is extremely important, along with overall potency including the clinically relevant protein adjusted antiviral activity that will be required for robust efficacy in long term durability trials. To date, no maturation inhibitor has achieved an optimal balance of these properties.
  • Li and L 2 are independently selected from a bond or [C(R 6 R 6 ')] q ;
  • W is selected from a bond or O;
  • R 1 is selected from the group consisting of hydrogen, (CrCi 2 )alkyl, -C(0)R 5 ,
  • R 2 is selected from the group consisting of -H, (Ci-C 12 )alkyl, -(C C 6 )alkyl-OR 4 , -(Ci-C 6 )alkyl-0-(Ci-C 6 )alk l, -C(0)R 5 , -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r N + (R 4 ) 3 , wherein when W is O, R 1 and R 2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 3 is selected from the group consisting of hydrogen, (CrCi 2 )alkyl,-NR 1 R 2 ,
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of -H, (d-CeJalkyl, -R 3 ,
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (C-i-C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -Y, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring, and wherein the cycloalkyi ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (CrC- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R 4 ) n , -NR 14 R 15 , -C(0)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 , wherein any two R 11 , R 12 or R 13 groups can optionally join to form a 3 to 8 membered cycloalkyi, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, and wherein the cycloalkyi, aryl, heterocyclyl or heteroary
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the cycloalkyi ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
  • R 16 is independently selected from the group consisting of -H, halo, oxo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , -N(R 4 ) 2 , -(CH 2 )rheterocyclyl, -C(0)OH,-C(0)NH 2 , -R 5 (R 9 ) q , -OR 5 (R 9 ) q , nitro, -S0 2 R 6 , -C(0)R 10 , and -CO(0)R 4 ;
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a) the compound of Formula I or Formula II or a
  • the present invention is a method of treating an HIV infection comprising administering to a subject suffering therefrom a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
  • Compounds of the present invention are useful for the treatment of subjects with an HIV infection or for the treatment of subjects at risk of acquiring an HIV infection.
  • Figure 1 shows a bar graph representing a comparison between
  • Figure 2 shows a bar graph representing a comparison between compound 51 and compound C of their relative ability to inhibit HIV reverse transcriptase activity across a broad panel of HIV-1 isolates.
  • Figure 3 shows a line graph representing an extrapolation of Bevirimat normalized IC 50 values to 100% human serum.
  • Figure 4 shows a line graph representing an extrapolation of compound B normalized IC 50 values to 100% human serum.
  • Figure 5 shows a line graph representing an extrapolation of compound 51 normalized IC 5 o values to 100% human serum.
  • alkyl refers to to a monovalent saturated aliphatic hydrocarbyl group having from 1 to 14 carbon atoms and, in some embodiments, from 1 to 6 carbon atoms.
  • (C x .C y )alkyl refers to alkyl groups having from x to y carbon atoms.
  • Alkylene or “alkylene” refers to divalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and, in some embodiments, from 1 to 6 carbon atoms.
  • (C u .C v )alkylene refers to alkylene groups having from u to v carbon atoms.
  • the alkylene groups include branched and straight chain hydrocarbyl groups.
  • (Ci.C 6 )alkylene” is meant to include methylene, ethylene, propylene, 2-methypropylene, dimethylethylene, pentylene, and so forth.
  • the term “propylene” could be exemplified by the following structure:
  • the term “dimethylbutylene” could be exemplified by any of the
  • (Ci_C 6 )alkylene is meant to include such branched chain hydrocarbyl groups as cyclopropylmethylene, which could be exemplified by the following structure:
  • Alkenyl refers to a linear or branched hydrocarbyl group having from
  • (C x -C y )alkenyl refers to alkenyl groups having from x to y carbon atoms and is meant to include for example, ethenyl, propenyl, isopropylene, 1 ,3-butadienyl, and the like.
  • Alkynyl refers to a linear monovalent hydrocarbon radical or a branched monovalent hydrocarbon radical containing at least one triple bond.
  • alkynyl is also meant to include those hydrocarbyl groups having one triple bond and one double bond.
  • (C 2 -C 6 )alkynyl is meant to include ethynyl, propynyl, and the like.
  • Alkoxy refers to the group -O-alkyl wherein alkyl is defined herein.
  • Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, f-butoxy, sec-butoxy, and n-pentoxy.
  • Acyl refers to the groups H-C(O)-, alkyl-C(O)-, alkenyl-C(O)-, alkynyl-C(O)-, cycloalkyl-C(O)-, aryl-C(O)-, heteroaryl-C(O)-, and heterocyclic-C(O)-.
  • Acyl includes the "acetyl” group CH 3 C(0)-.
  • R 20 is hydrogen or alkyl.
  • Acyloxy refers to the groups alkyl-C(0)0-, alkenyl-C(0)0-, alkynyl-C(0)0-, aryl-C(0)0-, cycloalkyl-C(0)0-, heteroaryl-C(0)0-, and
  • Amino refers to the group -NR 21 R 22 where R 21 and R 22 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyi, heteroaryl,
  • R 21 and R 22 are optionally joined together with the nitrogen bound thereto to form a heterocyclic group.
  • R 21 is hydrogen and R 22 is alkyl
  • the amino group is sometimes referred to herein as alkylamino.
  • R 21 and R 22 are alkyl, the amino group is sometimes referred to herein as dialkylamino.
  • a monosubstituted amino it is meant that either R 21 or R 22 is hydrogen but not both.
  • a disubstituted amino it is meant that neither R 21 nor R 22 are hydrogen.
  • Hydroxyamino refers to the group -NHOH.
  • Alkoxyamino refers to the group -NHO-alkyl wherein alkyl is defined herein.
  • Aminocarbonyl refers to the group -C(0)NR 26 R 27 where R 26 and R 27 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyi, heteroaryl, heterocyclic, hydroxy, alkoxy, amino, and acylamino, and where R 26 and R 27 are optionally joined together with the nitrogen bound thereto to form a heterocyclic group.
  • Aryl refers to an aromatic group of from 6 to 14 carbon atoms and no ring heteroatoms and having a single ring (e.g., phenyl) or multiple condensed (fused) rings (e.g. , naphthyl or anthryl).
  • a single ring e.g., phenyl
  • multiple condensed (fused) rings e.g. , naphthyl or anthryl.
  • the term “Aryl” or “Ar” applies when the point of attachment is at an aromatic carbon atom (e.g., 5,6,7,8 tetrahydronaphthalene-2-yl is an aryl group as its point of attachment is at the 2-position of the aromatic phenyl ring).
  • AUC refers to the area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration.
  • EC 50 refers to the concentration of a drug that gives half-maximal response.
  • IC 50 refers to the half-maximal inhibitory concentration of a drug.
  • Clade refers to a hypothetical construct based on experimental data.
  • Clades are found using multiple (sometimes hundreds) of traits from a number of species (or specimens) and analyzing them statistically to find the most likely phylogenetic tree for the group.
  • Cycloalkyl refers to a saturated or partially saturated cyclic group of from 3 to 14 carbon atoms and no ring heteroatoms and having a single ring or multiple rings including fused, bridged, and spiro ring systems.
  • cycloalkyl applies when the point of attachment is at a non-aromatic carbon atom (e.g. 5,6,7,8,-tetrahydronaphthalene-5-yl).
  • Cycloalkyl includes cycloalkenyl groups, such as cyclohexenyl.
  • cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl.
  • Examples of cycloalkyl groups that include multiple bicycloalkyl ring systems are bicyclohexyl, bicyclopentyl, bicyclooctyl, and the like. Two such bicycloalkyl multiple ring structures are exemplified and named below: bicyclohexyl, and bicyclohexyl.
  • (C u .C v )cycloalkyl refers to cycloalkyl groups having u to v carbon atoms.
  • Spiro cycloalkyl refers to a 3 to 10 member cyclic substituent formed by replacement of two hydrogen atoms at a common carbon atom in a cyclic ring structure or in an alkylene group having 2 to 9 carbon atoms, as exemplified by the following structure wherein the group shown here attached to bonds marked with wavy lines is substituted with a spiro cycloalkyl group:
  • Fused cycloalkyl refers to a 3 to 10 member cyclic substituent formed by the replacement of two hydrogen atoms at different carbon atoms in a cycloalkyl ring structure, as exemplified by the following structure wherein the cycloalkyl group shown here contains bonds marked with wavy lines which are bonded to carbon atoms that are substituted with a fused cycloalkyl group:
  • Halo or "halogen” refers to fluoro, chloro, bromo, and iodo.
  • Haloalkyl refers to substitution of an alkyl group with 1 to 3 halo groups (e.g., bifluoromethyl or trifluoromethyl).
  • Haloalkoxy refers to substitution of alkoxy groups with 1 to 5 (e.g. when the alkoxy group has at least 2 carbon atoms) or in some embodiments 1 to 3 halo groups (e.g. trifluoromethoxy).
  • Human Serum Protein Shift Assay refers to an HIV assay using a
  • Luciferase Reporter to determine percent inhibition - plC 50 .
  • the HIV assay makes use of a two-cell co-culture system. In this assay, an infected cell line J4HxB2 and an indicator cell line HOS (delta LTR + luciferase) are co-cultured in the presence and absence of compound. The assay is designed to find inhibitors that prevent the infection of HOS cells by the J4HxB2 cell line. The assay can detect inhibitors of any stage of the HIV infection cycle.
  • Heteroaryl refers to an aromatic group of from 1 to 14 carbon atoms and 1 to 6 heteroatoms selected from oxygen, nitrogen, and sulfur and includes single ring (e.g. imidazolyl) and multiple ring systems (e.g. benzimidazol-2-yl and benzimidazol-6-yl).
  • single ring e.g. imidazolyl
  • multiple ring systems e.g. benzimidazol-2-yl and benzimidazol-6-yl.
  • the term “heteroaryl” applies if there is at least one ring heteroatom and the point of attachment is at an atom of an aromatic ring (e.g.
  • the nitrogen and/or the sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N-oxide (N ⁇ 0), sulfinyl, or sulfonyl moieties.
  • heteroaryl includes, but is not limited to, pyridyl, furanyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, imidazolinyl, isoxazolyl, pyrrolyl, pyrazolyl, pyridazinyl, pyrimidinyl, purinyl, phthalazyl, naphthylpryidyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzothiazolyl,
  • Heterocyclic or “heterocycle” or “heterocycloalkyl” or “heterocyclyl” refers to a saturated or partially saturated cyclic group having from 1 to 14 carbon atoms and from 1 to 6 heteroatoms selected from nitrogen, sulfur, phosphorus or oxygen and includes single ring and multiple ring systems including fused, bridged, and spiro ring systems.
  • heterocyclic for multiple ring systems having aromatic and/or non- aromatic rings, the terms “heterocyclic”, “heterocycle”, “heterocycloalkyl”, or
  • heterocyclyl apply when there is at least one ring heteroatom and the point of attachment is at an atom of a non-aromatic ring (e.g. 1 ,2,3,4-tetrahydroquinoline-3-yl, 5,6,7,8-tetrahydroquinoline-6-yl, and decahydroquinolin-6-yl).
  • the nitrogen, phosphorus and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, phosphinane oxide, sulfinyl, sulfonyl moieties.
  • heterocyclyl includes, but is not limited to, tetrahydropyranyl, piperidinyl, piperazinyl, 3-pyrrolidinyl, 2-pyrrolidon-1 -yl, morpholinyl, and pyrrolidinyl.
  • a prefix indicating the number of carbon atoms (e.g., C3-C10) refers to the total number of carbon atoms in the portion of the heterocyclyl group exclusive of the number of heteroatoms.
  • heterocycle and heteroaryl groups include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, pyridone, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide,
  • fused heterocyclic or “fused heterocycle” refer to a 3 to 10 member cyclic substituent formed by the replacement of two hydrogen atoms at different carbon atoms in a cycloalkyi ring structure, as exemplified by the following structure wherein the cycloalkyi group shown here contains bonds marked with wavy lines which are bonded to carbon atoms that are substituted with a fused heterocyclic group:
  • Compound refers to a compound encompassed by the generic formulae disclosed herein, any subgenus of those generic formulae, and any forms of the compounds within the generic and subgeneric formulae, including the racemates, stereoisomers, and tautomers of the compound or compounds.
  • heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen, such as N(O) ⁇ N + — O " ⁇ and sulfur such as S(O) and S(O) 2 , and the quaternized form of any basic nitrogen.
  • Oxazolidinone refers to a 5-membered heterocyclic ring containing one nitrogen and one oxygen as heteroatoms and also contains two carbons and is substituted at one of the two carbons by a carbonyl group as exemplified by any of the following structures, wherein the oxazolidinone groups shown here are bonded to a parent molecule, which is indicated by a wavy line in the bond to the parent molecule:
  • Polymorphism refers to when two or more clearly different phenotypes exist in the same population of a species where the occurrence of more than one form or morph. In order to be classified as such, morphs must occupy the same habitat at the same time and belong to a panmictic population (one with random mating).
  • Protein binding refers to the binding of a drug to proteins in blood plasma, tissue membranes, red blood cells and other components of blood.
  • Protein shift refers to determining a binding shift by comparing the
  • QVT refers to the amino acids at positions 369, 370, and 371 , respectively in the Sp1 fragment of HIV-1 Gag.
  • Racemates refers to a mixture of enantiomers.
  • the compounds of Formula I, or pharmaceutically acceptable salts thereof are enantiomerically enriched with one enantiomer wherein all of the chiral carbons referred to are in one configuration.
  • enantiomerically enriched compound or salt is meant to indicate that the specified enantiomer will comprise more than 50% by weight of the total weight of all enantiomers of the compound or salt.
  • Solvate or “solvates” of a compound refer to those compounds, as defined above, which are bound to a stoichiometric or non-stoichiometric amount of a solvent.
  • Solvates of a compound includes solvates of all forms of the compound.
  • solvents are volatile, non-toxic, and/or acceptable for administration to humans in trace amounts. Suitable solvates include water.
  • Stereoisomer or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
  • the term 'atropisomer' refers to a stereoisomer resulting from an axis of asymmetry. This can result from restricted rotation about a single bond where the rotational barrier is high enough to allow differentiation of the isomeric species up to and including complete isolation of stable non-interconverting diastereomer or enantiomeric species.
  • the rotational barrier is high enough to allow differentiation of the isomeric species up to and including complete isolation of stable non-interconverting diastereomer or enantiomeric species.
  • interconversion between the atropisomers may or may not be possible and may depend on temperature.
  • the atropisomers may interconvert rapidly at room temperature and not resolve under ambient conditions.
  • Other situations may allow for resolution and isolation but interconversion can occur over a period of seconds to hours or even days or months such that optical purity is degraded measurably over time.
  • Yet other species may be completely restricted from interconversion under ambient and/or elevated temperatures such that resolution and isolation is possible and yields stable species.
  • the resolved atropisomers were named using the helical nomenclature. For this designation, only the two ligands of highest priority in front and behind the axis are considered. When the turn priority from the front ligand 1 to the rear ligand 1 is clockwise, the configuration is P, if counterclockwise it is M.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium, and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, and oxalate. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection, and Use; 2002.
  • Patient or “subject” refers to mammals and includes humans and non-human mammals.
  • Treating or “treatment” of a disease in a patient refers to 1 ) preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the disease; 2) inhibiting the disease or arresting its
  • dashed line represents an optional double bond at that position.
  • dashed circles appear within ring structures denoted by solid lines or solid circles, then the dashed circles represent one to three optional double bonds arranged according to their proper valence taking into account whether the ring has any optional substitutions around the ring as will be known by one of skill in the art.
  • the dashed line in the structure below could either indicate a t position or a single bond at that position:
  • ring A below could be a cyclohexyl ring without any double bonds or it could also be a phenyl ring having three double bonds arranged in any position that still depicts the proper valence for a phenyl ring.
  • any of X 1 -X 5 could be selected from: C, CH, or CH 2 , N, or NH, and the dashed circle means that ring B could be a cyclohexyl or phenyl ring or a N-containing heterocycle with no double bonds or a N-containing heteroaryl ring with one to three double bonds arranged in any position that still depicts the proper valence:
  • the present invention includes compounds as well as their pharmaceutically acceptable salts. Accordingly, the word “or” in the context of "a compound or a pharmaceutically acceptable salt thereof” is understood to refer to either: 1 ) a compound alone or a compound and a pharmaceutically acceptable salt thereof (alternative), or 2) a compound and a pharmaceutically acceptable salt thereof (in combination).
  • Bevirimat is a yet unapproved anti-HIV drug derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chinese herb. It is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition. Like protease inhibitors, Bevirimat and other maturation inhibitors interfere with protease processing of newly translated HIV polyprotein precursor, called gag. Gag is an essential structural protein of the HIV virus. Gag undergoes a chain of interactions both with itself and with other cellular and viral factors to accomplish the assembly of infectious virus particles.
  • Li and L 2 are independently selected from a bond or [C(R 6 R 6 ')] q ;
  • W is selected from a bond or O
  • R 1 i selected from the group consisting of -H, (CrCi 2 )alkyl, -C(0)R 5
  • R 2 is selected from the group consisting of -H, (Ci-C 12 )alkyl, -(C C 6 )alkyl-OR 4 ,
  • R 1 and R 2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 3 is selected from the group consisting of -H, (Ci-Ci 2 )alkyl,-NR 1 R 2 , -OR 5 , wherein:
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -Cg)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of -H, (CrC 6 )alkyl, -R 3 ,
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (d-C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -Y, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, and wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R 4 ) n , -NR 14 R 15 , -C(0)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, - C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 , wherein any two R 11 , R 12 or R 13 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, and wherein the cycloalkyi, aryl, heterocyclyl or heteroary
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the cycloalkyi ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
  • R 16 is independently selected from the group consisting of -H, halo, oxo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q ,
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • Li and L 2 are [C(R 6 R 6 ')] q ;
  • W is selected from a bond or O
  • R 1 is selected from the group consisting of -H, (CrC 6 )alkyl, -C(0)R 4 , and
  • R 2 is selected from the group consisting of -H, (C C 6 )alkyl, -(C C 6 )alkyl-OR 4 -(Ci-C 6 )alkyl-0-(Ci-C 6 )alk l, -C(0)R 5 , -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r N + (R 4 ) 3 ;
  • R 3 is selected from the group consisting of hydrogen, (CrCi 2 )alkyl,-NR 1 R 2 , -
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of (d-CeJalkyl, -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r OR 7 ;
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (d-C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring, and wherein the cycloalkyi ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (CrC- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -NR 14 R 15 , and -C(0)CH 3 ;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 ;
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 ;
  • R 16 is independently selected from the group consisting of -H, oxo, halo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q ,
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • Li and L 2 are both (-CH 2 -);
  • W is O
  • R 1 is -H
  • R 2 is selected from the group consisting of -H, (C C 6 )alkyl, -(C C 6 )alkyl-OR 4 , -(Ci-C 6 )alkyl-0-(Ci-C 6 )alk l, -C(0)R 5 , and -(CH 2 ) r NR 7 R 8 ;
  • R 3 is selected from the group consisting of -H, (CrCi 2 )alkyl,-NR 1 R 2 , , wherein:
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of (CrC 6 )alkyl, -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r OR 7 ;
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (CrC- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 ;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -NR 14 R 15 , and -C(0)CH 3 ;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 ;
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 ;
  • R 16 is independently selected from the group consisting of -H, oxo, halo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , -N(R 4 ) 2 , -(CH 2 ) r -heterocyclyl, -C(0)OH,-C(0)NH 2 , -R 5 (R 9 ) q , -OR 5 (R 9 ) q , nitro, -S0 2 R 6 , -C(0)R 10 , and -CO(0)R 4 ;
  • n and n in each instance are independently 0, 1 , or 2;
  • p is independently 0, 1 , or 2;
  • r and q in each instance are independently 0, 1 , 2, or 3.
  • Li and L 2 are both (-CH 2 -);
  • W is O
  • R 1 is -H
  • R 2 is selected from the group consisting of -H, (CrC 6 )alkyl, -C(0)R 5 , and
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of (CrC 6 )alkyl, -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r OR 7 ;
  • R 6 is selected from the group consisting of -H, (CrC 6 )alkyl, (C 3 -C 8 )cycloalkyl, (CrC 6 )alkoxy, haloalkyl, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 ;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -NR 14 R 15 , and -C(0)CH 3 ;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkox , -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (Ci-C 6 )alkyl, -C(0)R 10 , -CO(0)R 4 , and -CO(0)R 5 ;
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 ;
  • R 16 is independently selected from the group consisting of -H, oxo, halo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q ,
  • n and n in each instance are independently 0, 1 , or 2;
  • p is independently 0, 1 , or 2;
  • r and q in each instance are independently 0, 1 , 2, or 3.
  • W is O
  • R is -H
  • R 2 is - CH 2 ) r NR 7 R 8 ; , wherein X is phenyl;
  • R 7 and R 8 are independently selected from the group consisting of -H and methyl
  • R 9 is selected from the group consisting of chloro, bromo, and fluoro
  • R 11 is selected from the group consisting of chloro, bromo, and fluoro
  • m is 0, 1 , or 2;
  • r is 1 , 2, or 3.
  • Li and L 2 are independently selected from a bond or [C(R 6 R 6 ')] q each instance of Q is independently selected from -CH 2 - or -C( W is selected from a bond or O;
  • R 1 is selected from the group consisting of -H, (CrC 12 )alkyl, -C(0)R 5 , -CH 2 -0-
  • R 2 is selected from the group consisting of -H, (Ci-C 12 )alkyl, -(C C 6 )alkyl-OR 4 , -(Ci-C 6 )alkyl-0-(Ci-C 6 )alk l, -C(0)R 5 , -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r N + (R 4 ) 3 , wherein when W is O, R 1 and R 2 can optionally be taken together with the O and N to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 3 is selected from the group consisting of hydrogen, (CrCi 2 )alkyl,-NR 1 R 2 ,
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of -H, (d-CeJalkyl, -R 3 ,
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (d-C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -Y, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring, and wherein the cycloalkyi ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (CrC- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R 4 ) n , -NR 14 R 15 , -C(0)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 , wherein any two R 11 , R 12 or R 13 groups can optionally join to form a 3 to 8 membered cycloalkyi, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, and wherein the cycloalkyi, aryl, heterocyclyl or heteroary
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the cycloalkyi ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
  • R 16 is independently selected from the group consisting of -H, halo, oxo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , -N(R 4 ) 2 , -(CH 2 )rheterocycle, -C(0)OH,-C(0)NH 2 , -R 5 (R 9 ) q , -OR 5 (R 9 ) q , nitro, -S0 2 R 6 ,
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • A is R4" ° ( Q ⁇ ( Q >i ;
  • Li and L 2 are [C(R 6 R 6 ')] q ;
  • W is selected from a bond or O
  • R 1 is selected from the group consisting of -H, (d-CeJalkyl, -C(0)R 4 , and
  • R 2 is selected from the group consisting of -H, (C C 6 )alkyl, -(C C 6 )alkyl-OR 4 , -(Ci-C 6 )alkyl-0-(Ci-C 6 )alk l, -C(0)R 5 , -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r N + (R 4 ) 3 ;
  • R 3 is selected from the group consisting of -H, (CrCi 2 )alkyl, -NR 1 R 2 , . wherein:
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -C 9 )heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 4 is selected from the group consisting of -H and (CrC 6 )alkyl
  • R 5 is selected from the group consisting of (CrC 6 )alkyl, -(CH 2 ) r NR 7 R 8 , and -(CH 2 ) r OR 7 ;
  • R 6 and R 6 ' are independently selected from the group consisting of -H, (d-C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring, and wherein the cycloalkyi ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -NR 14 R 15 , and -C(0)CH 3 ;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (Ci-C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , -CO(0)R 4 , and -CO(0)R 5 ;
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 ;
  • R 16 is independently selected from the group consisting of -H, oxo, halo, hydroxyl, (d-C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , -N(R 4 ) 2 , -(CH 2 )rheterocycle, -C(0)OH,-C(0)NH 2 , -R
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • Li and L 2 are both (-CH 2 -);
  • W is O
  • R 1 is -H
  • R 2 is selected from the group consisting of -H, (CrC 6 )alkyl, -C(0)R 5 , and - (CH 2 ) r NR 7 R 8 ; , wherein X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl;
  • R 4 is selected from the group consisting of -H and (d-CeJalkyl;
  • R 5 is selected from the group consisting of (CrC 6 )alkyl, -(CH 2 ) r NR 7 R 8 , and -(CH 2 )rOR 7 ;
  • R 6 is selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (CrC 6 )alkoxy, haloalkyl, -(CH 2 ) r NR 7 R 8 , -C(0)OH, and -C(0)NH 2 ;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -NR 14 R 15 , and -C(0)CH 3 ;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl,
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 ;
  • R 16 is independently selected from the group consisting of -H, oxo, halo, hydroxyl, (C C 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q ,
  • n and n in each instance are independently 0, 1 , or 2;
  • p is independently 0, 1 , or 2;
  • r and q in each instance are independently 0, 1 , 2, or 3.
  • Li and L 2 are both (-CH 2 -);
  • W is O
  • R 1 is -H
  • R 2 is - CH 2 ) r NR 7 R 8 ;
  • R is , wherein X is phenyl
  • R 7 and R 8 are independently selected from the group consisting of -H and methyl
  • R 9 is selected from the group consisting of chloro, bromo, and fluoro
  • R 11 is selected from the group consisting of chloro, bromo, and fluoro
  • m is 0, 1 , or 2;
  • r is 1 , 2, or 3.
  • Li and L 2 are independently selected from a bond or [C(R 6 R 6 )] q ;
  • W is selected from a bond or oxygen
  • R 1 is selected from the group consisting of -H, (C Ci 2 )alkyl,-C(0)R 5 , -CH 2 -0-
  • R 2 is selected from the group consisting of -H, (C Ci 2 )alkyl, -Ci_ 6 alkyl-OH,
  • R 1 and R 2 can optionally be taken together with the oxygen and nitrogen to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 3 is selected from the group consisting of hydrogen, (CrCi 2 )alkyl,-NR 1 R 2 ,
  • X is a monocyclic or bicyclic (C 5 -Ci 4 )aryl
  • Y is selected from a monocyclic or bicyclic (C 2 -C 9 )heterocyclyl or monocylic or bicyclic (C 2 -Cg)heteroaryl, each having one to three heteroatoms selected from S, N or O, and
  • Z is a monocyclic or bicyclic (C 3 -C 8 )cycloalkyl
  • R 2 and R 3 can optionally be taken together with the nitrogen and L 2 to which they are respectively joined to form a 4 to 8 membered heterocyclyl ring, wherein the heterocyclyl ring may be optionally substituted by one to two R 11 groups;
  • R 4 is selected from -H and (CrC 6 )alkyl
  • R 5 is selected from (C C 6 )alkyl, -R 3 , -(CH 2 ) r NR 7 R 8 , or -(CH 2 ) r OR 7 ;
  • R 6 and R 6 ' are independently -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, haloalkyl, -Y, -(CH 2 ) r NR 7 R 8 , -C(0)OH, -C(0)NH 2 , wherein the R 6 and R 6 ' groups can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyl ring, wherein the cycloalkyl ring may be optionally substituted by one to three R 11 groups;
  • R 7 and R 8 are independently selected from the group consisting of -H, (C C- 6 )alkyl, (C 3 -C 8 )cycloalkyl, -Q-aryl-(R 4 ) n , -NR 14 R 15 , -C(0)CH 3 , wherein R 7 and R 8 can optionally be taken together with the nitrogen to which they are joined to form a 4 to 8 membered heterocyclyl or heteroaryl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the heterocyclyl or heteroaryl ring may be optionally substituted by one to three R 11 groups;
  • R 9 is halo
  • R 10 is -N(R 16 ) 2 ;
  • R 11 , R 12 , and R 13 are independently selected from the group consisting of oxo, hydroxyl, halo, (C C 6 )alkoxy, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , nitro, -S0 2 R 6 , (C C 6 )alkyl, -C(0)R 10 , -R 4 YR 6 , and -CO(0)R 5 , wherein any two R 9 , R 10 or R 11 groups can optionally join to form a 3 to 8 membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring, wherein the heterocyclyl or heteroaryl ring may contain one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, and wherein the cycloalkyi, aryl, heterocyclyl or heteroaryl ring may be optionally substitute
  • R 14 and R 15 are independently selected from the group consisting of -H, (C C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C C 6 )alkoxy, -[C(R 6 ) 2 ] r , -0[C(R 6 ) 2 ] r , oxo, hydroxyl, halo, -C(0)R 7 , -R 10 , and -CO(0)R 2 , wherein R 14 and R 15 can optionally be taken together with the carbon to which they are joined to form a 3 to 8 membered cycloalkyi ring or 4 to 8 membered heterocyclyl ring containing one to three heteroatoms selected from -NR 5 -, -0-, -S-, -S(O)-, or -S0 2 -, wherein the cycloalkyi ring or heterocyclyl ring may be optionally substituted by one to three R 16 groups;
  • R 16 is independently selected from the group consisting of halo, oxo, hydroxyl, (CrC 6 )alkyl, (C C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, -R 6 (R 9 ) q , -OR 6 (R 9 ) q , -N(R 4 ) 2 , -(CH 2 ) r - heterocyclyl, -C(0)OH,-C(0)NH 2 , -R 5 (R 9 ) q , -OR 5 (R 9 ) q , nitro, -S0 2 R 6 , -C(0)R 10 , and -CO(0)R 4 ;
  • n and n in each instance are independently 0, 1 , 2, 3, or 4;
  • p is independently 0, 1 , 2, 3, or 4;
  • r and q in each instance are independently 0, 1 , 2, 3, or 4.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
  • a method of treating HIV comprising administering to a patient suffering therefrom an effective amount of a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the compound is present in an amorphous form.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the composition is in a tablet form.
  • a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the compound is present as a spray dried dispersion.
  • a method of treating an HIV infection in a subject comprising administering to the subject a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
  • the subject is a mammal, and in other words
  • the subject is a human.
  • a method of treating an HIV infection in a subject comprising administering to the subject a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • a method of preventing an HIV infection in a subject at risk for developing an HIV infection comprising administering to the subject a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
  • a method of preventing an HIV infection in a subject at risk for developing an HIV infection comprising administering to the subject a pharmaceutical composition comprising a compound of Formula I or Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • the present invention also provides the use of a compound or salt as defined in any of Formula I or Formula II in the manufacture of a medicament for use in the treatment of an HIV infection in a human.
  • the compounds of the invention can exist in particular geometric or stereoisomeric forms.
  • the invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, as falling within the scope of the invention.
  • Additional asymmetric carbon atoms can be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • Optically active (R)- and (S)-isomers and d and I isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If, for instance, a particular enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis, or by derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • diastereomeric salts can be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.
  • separation of enantiomers and diastereomers is frequently accomplished using chromatography employing chiral, stationary phases, optionally in combination with chemical derivatization (e.g., formation of carbamates from amines).
  • a compound of Formula I or Formula II wherein the compound or salt of the compound is used in the manufacture of a medicament for use in the treatment of a viral infection in a human.
  • a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound as defined in Formula I.
  • the pharmaceutical formulation containing a compound of Formula I or Formula II or a salt thereof is a formulation adapted for parenteral administration.
  • the formulation is a long-acting parenteral formulation.
  • the formulation is a nano-particle formulation.
  • the compounds of the present invention and their salts, solvates, or other pharmaceutically acceptable derivatives thereof may be employed alone or in combination with other therapeutic agents. Therefore, in other embodiments, the methods of treating and/or preventing an HIV infection in a subject may in addition to administration of a compound of Formula I or Formula II further comprise administration of one or more additional pharmaceutical agents active against HIV.
  • the one or more additional agents active against HIV is selected from the group consisting of zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lersivirine, GSK2248761 , TMC- 278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasina
  • the compounds of the present invention and any other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order.
  • the amounts of the compounds of the present invention and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the administration in combination of a compound of the present invention and salts, solvates, or other pharmaceutically acceptable derivatives thereof with other treatment agents may be in combination by administration concomitantly in: (1 ) a unitary pharmaceutical composition including both compounds; or (2) separate pharmaceutical compositions each including one of the compounds.
  • the combination may be administered separately in a sequential manner wherein one treatment agent is administered first and the other second or vice versa. Such sequential administration may be close in time or remote in time.
  • pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
  • the compounds of the present invention may be used in combination with one or more other agents useful in the prevention or treatment of HIV.
  • Nucleotide reverse transcriptase inhibitors such as zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, and similar agents;
  • Non-nucleotide reverse transcriptase inhibitors including an agent having anti-oxidation activity such as immunocal, oltipraz, etc.
  • an agent having anti-oxidation activity such as immunocal, oltipraz, etc.
  • GSK2248761 TMC-278, TMC-125, etravirine, and similar agents;
  • Protease inhibitors such as saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, and similar agents;
  • Entry, attachment and fusion inhibitors such as enfuvirtide (T-20), T- 1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5- Helix and similar agents;
  • Inteqrase inhibitors such as raltegravir, elvitegravir, GSK1349572, GSK1265744 and similar agents;
  • Maturation inhibitors such as PA-344 and PA-457, and similar agents.
  • CXCR4 and/or CCR5 inhibitors such as vicriviroc (Sch-C), Sch-D, TAK779, maraviroc (UK 427,857), TAK449, as well as those disclosed in WO
  • the present invention may be used in combination with one or more agents useful as pharmacological enhancers as well as with or without additional compounds for the prevention or treatment of HIV. Examples of such agents useful as pharmacological enhancers as well as with or without additional compounds for the prevention or treatment of HIV. Examples of such agents useful as pharmacological enhancers as well as with or without additional compounds for the prevention or treatment of HIV. Examples of such agents
  • pharmacological enhancers include, but are not limited to, ritonavir, GS-9350, and SPI-452.
  • Ritonavir is 10-hydroxy-2-methyl-5-(1 -methyethyl)-1 -1 [2-(1 - methylethyl)-4-thiazolyl]-3,6-dioxo-8, 1 1 -bis(phenylmethyl)-2,4,7, 12-tetraazatridecan- 13-oic acid, 5-thiazolylmethyl ester, [5S-(5S*,8R*, 10R*, 1 1 R*)] and is available from Abbott Laboratories of Abbott park, Illinois, as Norvir.
  • Ritonavir is an HIV protease inhibitor indicated with other antiretroviral agents for the treatment of HIV infection. Ritonavir also inhibits P450 mediated drug metabolism as well as the P-gycoprotein (Pgp) cell transport system, thereby resulting in increased concentrations of active compound within the organism.
  • Pgp P-gycoprotein
  • GS-9350 is a compound being developed by Gilead Sciences of Foster City California as a pharmacological enhancer.
  • SPI-452 is a compound being developed by Sequoia Pharmaceuticals of Gaithersburg, Maryland, as a pharmacological enhancer.
  • a compound of Formula I or Formula II is used in combination with ritonavir.
  • the combination is an oral fixed dose combination.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and ritonavir is formulated as an oral composition.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and ritonavir is formulated as an injectable composition.
  • a compound of Formula I or Formula II is used in combination with GS-9350.
  • the combination is an oral fixed dose combination.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and GS-9350 is formulated as an oral composition.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and GS-9350 is formulated as an injectable composition.
  • is a kit containing the compound of Formula I or Formula II is formulated as a long acting parenteral injection and GS-9350 formulated as an injectable composition.
  • a compound of Formula I or Formula II is used in combination with SPI-452.
  • the combination is an oral fixed dose combination.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and SPI-452 is formulated as an oral composition.
  • the compound of Formula I or Formula II is formulated as a long acting parenteral injection and SPI-452 is formulated as an injectable composition.
  • a compound of Formula I or Formula II is used in combination with compounds which are found in previously filed PCT/CN201 1/0013021 , which is herein incorporated by reference.
  • a method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula I or Formula II.
  • a method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula I or Formula II, wherein said virus is an HIV virus.
  • the HIV virus is the HIV-1 virus.
  • a method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula I or Formula II, further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus.
  • a method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound of Formula I or Formula II, further comprising administration of a therapeutically effective amount of one or more agents active against the HIV virus, wherein said agent active against HIV virus is selected from Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry, attachment and fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CXCR4 inhibitors; and CCR5 inhibitors.
  • the compound of the present invention, or a pharmaceutically acceptable salt thereof is chosen from the compounds set forth in Table 2.
  • the compound(s) of the present invention is chosen from the compounds set forth in Table 2.
  • Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • the methods of this invention may employ protecting groups which prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
  • the provided chemical entities may contain one or more chiral centers and such compounds can be prepared or isolated as pure
  • stereoisomers i.e., as individual enantiomers or diastereomers, or as stereoisomer- enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this specification, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
  • the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
  • many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Ernka-Chemce or Sigma (St. Louis, Missouri, USA).
  • reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a temperature range of about -78 °C to about 1 10 °C over a period of about 1 to about 24 hours; reactions left to run overnight average a period of about 16 hours.
  • solvent each mean a solvent inert under the conditions of the reaction being described in conjunction therewith, including, for example, benzene, toluene, acetonitrile, tetrahydrofuranyl (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, N-methylpyrrolidone (“NMP”), pyridine and the like.
  • solvent solvent inert under the conditions of the reaction being described in conjunction therewith, including, for example, benzene, toluene, acetonitrile, tetrahydrofuranyl (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, N-methylpyrrolidone (“NMP”), pyridine and the like.
  • THF tetrahydrofuranyl
  • DMF dimethylformamide
  • Isolation and purification of the chemical entities and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples herein below.
  • the (R)- and (S)-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • a specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other
  • inhibitory concentration at 50% inhibition J coupling constant (given in Hz unless otherwise
  • nm nanomolar
  • Solvent A 0.01 % trifluoroacetic acid (TFA) in water;
  • Solvent B 0.01 % TFA in acetonitrile
  • the organic phase was washed successively with: water (100 mL), a saturated solution of sodium carbonate (100 mL x 2) and brine (100 mL ⁇ 2), then dried over sodium sulfate, and concentrated under reduced pressure to afford a sticky oil.
  • the sticky oil was triturated with MeOH (250 mL) and the precipitates were collected to give the intermediate 4 (6 g, 1 1.1 mmol, 83 %) as a white solid.
  • Example 5 Compound 32 4-(((3aR, 5aR, 5bR, laR, 9S, 11aR, 11bR, 13aS)-3a-(2-((4-Chlorobenzyl)amino)ethyl)-1- isopropyl-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
  • Step F Intermediate 31 4-((3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-(2-((Tert-butoxycarbonyl)(4- chlorobenzyl)amino)ethyl)-1-isopropyl-5a, 5b, 8, 8, 11 a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) 1-tert-butyl 2,2-dimethylsuccinate
  • Example 7 Compound 39 -(((3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-(2-((3-Chlorobenzyl)amino)ethyl)-1- isopropyl-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
  • Step A Compound 34 (3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-(2-Aminoethyl)-1-isopropyl-
  • Step F Compound 39 4-(((3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-(2-((3-Chlorobenzyl)amino)ethyl)-1- isopropyl-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
  • reaction mixture was stirred at 20 °C for 2 h.
  • the reaction mixture was then cooled to 0 °C and NaBH 4 (1.541 g, 40.7mmol) was added in portions within 30 min, after which the solution was allowed to stirred for 1 h.
  • the mixture was purified by preparative-TLC eluting with DCM/MeOH (20 :1 ) to give 39 (108 mg, 0.147 mmol, 29 %).
  • reaction solution was stirred at rt for another 1.5 h, and the product was extracted with DCM (60 ml_ * 3), and the combined organic phase was washed with brine (100 ml), dried over Na 2 S0 4 , concentrated and the residue was purified by recrystallization from DCM and hexane (1 :6) resulting in 800 mg of the TFA salt of 41 as white solid.
  • the reaction mixture was stirred at 40 °C for 2 h.
  • the reaction was cooled to rt and sodium cyanoborohydride (24.84 mg, 0.395 mmol) was added and the resultant solution was stirred overnight.
  • the reaction was diluted with ammonium chloride (40 ml), and extracted with DCM (60 ml x 3). The combined organic layers were washed with brine (20 ml), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative-HPLC to afford 42 as a trifluoroacetic acid salt (200 mg, 49 % yield) as a white solid.
  • Example 22 and 23 Compound 62 and 63 5-(((3aR, 5aR, 5bR, 7aR, 9S, 11aR,11bR, 13aS)-3a-((R)-2-((4-Chlorobenzyl)(2- (dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentam
  • Step D Compounds 62 and 63
  • Example 24 Compound 64 4-(((3aR, 5aR, 5bR, laR, 9S, 11aR, 11bR, 13aS)-3a-((S)-2-((2-Chlorobenzyl)amino)-1- hydroxyethyl)-1-isopropyl-5a, 5b, 8, 8, 11 a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
  • reaction mixture was stirred at rt for 2 h. Then it was added NaCNBH 3 (85 mg, 1.345 mmol) portionwise and stirred for overnight. The solvent was evaporated and the the residue diluted with DCM and washed with water and brine.
  • Example 40 Compound 81 4-(((3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-((R)-1-Acetoxy-2-((3- chlorobenzyl)amino)ethyl)-1-isopropyl-5a, 5b, 8, 8, 11 a-pentamethyl-2-oxo- 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8,9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/US2012/069637 2011-12-16 2012-12-14 Derivatives of betulin WO2013090664A1 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
RS20170937A RS56373B1 (sr) 2011-12-16 2012-12-14 Derivati betulina
LTEP12857774.9T LT2791103T (lt) 2011-12-16 2012-12-14 Betulino dariniai
US14/365,802 US20150218142A1 (en) 2011-12-16 2012-12-14 Derivatives of Betulin
JP2014547462A JP6300730B2 (ja) 2011-12-16 2012-12-14 ベツリンの誘導体
SI201231079T SI2791103T1 (sl) 2011-12-16 2012-12-14 Derivati betulina
EP12857774.9A EP2791103B1 (en) 2011-12-16 2012-12-14 Derivatives of betulin
SG11201402707PA SG11201402707PA (en) 2011-12-16 2012-12-14 Derivatives of betulin
DK12857774.9T DK2791103T3 (en) 2011-12-16 2012-12-14 DERIVATIVES OF BETULIN
CN201280069739.7A CN105008322B (zh) 2011-12-16 2012-12-14 白桦脂醇的衍生物
BR112014014769-8A BR112014014769A2 (pt) 2011-12-16 2012-12-14 Composto, composição farmacêutica, e, uso de um composto ou sal.
MX2014007280A MX360679B (es) 2011-12-16 2012-12-14 Derivados de betulina.
AU2012352110A AU2012352110B2 (en) 2011-12-16 2012-12-14 Derivatives of betulin
PL12857774T PL2791103T3 (pl) 2011-12-16 2012-12-14 Pochodne betuliny
CA2859030A CA2859030C (en) 2011-12-16 2012-12-14 Derivatives of betulin
UAA201406100A UA116978C2 (uk) 2011-12-16 2012-12-14 Похідні бетуліну
KR1020147019864A KR101953869B1 (ko) 2011-12-16 2012-12-14 베툴린의 유도체
EA201490919A EA027363B1 (ru) 2011-12-16 2012-12-14 Производные бетулина
ES12857774.9T ES2644578T3 (es) 2011-12-16 2012-12-14 Derivados de betulina
MEP-2017-198A ME02895B (me) 2011-12-16 2012-12-14 Derivati betulina
NZ625516A NZ625516B2 (en) 2011-12-16 2012-12-14 Derivatives of betulin
ZA2014/04135A ZA201404135B (en) 2011-12-16 2014-06-05 Derivatives of betulin
IL233081A IL233081A (en) 2011-12-16 2014-06-12 History of Batolin
MA37132A MA35833B1 (fr) 2011-12-16 2014-06-13 Dérivés de bétuline
PH12014501362A PH12014501362A1 (en) 2011-12-16 2014-06-16 Derivatives of betulin
US14/757,754 US20160120878A1 (en) 2011-12-16 2015-12-23 Derivatives of betulin
PH12017501426A PH12017501426A1 (en) 2011-12-16 2017-08-09 Derivatives of betulin
PH12017501429A PH12017501429A1 (en) 2011-12-16 2017-08-09 Derivatives of betulin
US15/685,150 US20170348324A1 (en) 2011-12-16 2017-08-24 Derivatives of betulin
CY20171101043T CY1119422T1 (el) 2011-12-16 2017-10-06 Παραγωγα μπετουλινης
HRP20171512TT HRP20171512T1 (hr) 2011-12-16 2017-10-09 Derivati betulina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576448P 2011-12-16 2011-12-16
US61/576,448 2011-12-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/365,802 A-371-Of-International US20150218142A1 (en) 2011-12-16 2012-12-14 Derivatives of Betulin
US14/757,754 Continuation US20160120878A1 (en) 2011-12-16 2015-12-23 Derivatives of betulin

Publications (1)

Publication Number Publication Date
WO2013090664A1 true WO2013090664A1 (en) 2013-06-20

Family

ID=48613199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/069637 WO2013090664A1 (en) 2011-12-16 2012-12-14 Derivatives of betulin

Country Status (38)

Country Link
US (6) US20150218142A1 (xx)
EP (2) EP2791103B1 (xx)
JP (2) JP6300730B2 (xx)
KR (1) KR101953869B1 (xx)
CN (2) CN107501383A (xx)
AR (1) AR089285A1 (xx)
AU (1) AU2012352110B2 (xx)
BR (1) BR112014014769A2 (xx)
CA (1) CA2859030C (xx)
CL (1) CL2014001585A1 (xx)
CO (1) CO6970600A2 (xx)
CR (1) CR20140301A (xx)
CY (1) CY1119422T1 (xx)
DK (1) DK2791103T3 (xx)
DO (1) DOP2014000121A (xx)
EA (2) EA201790923A1 (xx)
ES (1) ES2644578T3 (xx)
HK (1) HK1210180A1 (xx)
HR (1) HRP20171512T1 (xx)
HU (1) HUE034877T2 (xx)
IL (1) IL233081A (xx)
JO (1) JO3387B1 (xx)
LT (1) LT2791103T (xx)
MA (1) MA35833B1 (xx)
ME (1) ME02895B (xx)
MX (1) MX360679B (xx)
PE (1) PE20141788A1 (xx)
PH (3) PH12014501362A1 (xx)
PL (1) PL2791103T3 (xx)
PT (1) PT2791103T (xx)
RS (1) RS56373B1 (xx)
SG (1) SG11201402707PA (xx)
SI (1) SI2791103T1 (xx)
TW (2) TWI583696B (xx)
UA (1) UA116978C2 (xx)
UY (1) UY34523A (xx)
WO (1) WO2013090664A1 (xx)
ZA (1) ZA201404135B (xx)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2812343A4 (en) * 2012-02-08 2015-12-02 Jiangxi Qingfeng Pharmaceutical Inc Lupane triterpene derivatives and their pharmaceutical use
JP2016503030A (ja) * 2012-12-14 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 医薬組成物
WO2016046786A1 (en) 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
WO2016077572A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Extended betulinic acid analogs
WO2016178092A2 (en) 2015-02-09 2016-11-10 Hetero Research Foundation C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
WO2017017607A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017051355A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
CN107250153A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 氧代羽扇豆烯衍生物
US9868758B2 (en) 2014-06-30 2018-01-16 Hetero Labs Limited Betulinic proline imidazole derivatives as HIV inhibitors
US10064873B2 (en) 2011-12-16 2018-09-04 Glaxosmithkline Llc Compounds and compositions for treating HIV with derivatives of Betulin
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019186342A1 (en) 2018-03-27 2019-10-03 Glaxosmithkline Intellectual Property (No.2) Limited Ionic liquid salts of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019207460A1 (en) 2018-04-24 2019-10-31 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9863858B2 (en) * 2014-02-12 2018-01-09 Ofi Testing Equipment, Inc. Heating and cooling jacket for test cell
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018044853A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Conpany Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2002074769A1 (fr) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane
WO2004055016A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
WO2004054974A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
US20060205697A1 (en) * 2004-11-12 2006-09-14 Robinson Gary N Novel betulin derivatives, preparation thereof and use thereof
WO2009082818A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
WO2010053817A1 (en) * 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US20100190795A1 (en) * 2006-06-07 2010-07-29 Valtion Teknillinen Tutkimuskeskus Betulin derived compounds useful as antiprotozoal agents
WO2011010038A1 (fr) 2009-07-20 2011-01-27 Institut Francais Textile Et Habillement Association de produits cationiques et anioniques naturels comme liant pour support textile
WO2011100308A1 (en) 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
US20110218204A1 (en) * 2009-07-14 2011-09-08 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of novel betulinic acid derivatives
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013091144A1 (en) 2011-12-21 2013-06-27 Glaxosmithkline Llc Propenoate derivatives of betulin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
AU2001262489A1 (en) 2000-05-23 2001-12-03 Univerzita Karlova V Praze Triterpenoid derivatives
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
WO2006105356A2 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006117666A2 (en) 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
CA2643028A1 (en) 2006-02-21 2007-08-30 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
PE20080210A1 (es) 2006-06-23 2008-04-11 Tibotec Pharm Ltd Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278)
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
TW200837074A (en) * 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
AU2008342537A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
CZ2008723A3 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
ES2641765T3 (es) 2008-12-11 2017-11-13 Shionogi & Co., Ltd. Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
KR20140101869A (ko) 2011-12-14 2014-08-20 글락소스미스클라인 엘엘씨 베툴린의 프로페노에이트 유도체
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN104844679B (zh) * 2011-12-16 2017-03-01 葛兰素史克有限责任公司 白桦脂醇的衍生物
WO2014035945A1 (en) 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
EA201590862A1 (ru) 2012-12-14 2016-05-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Фармацевтические композиции
PE20170691A1 (es) 2014-09-26 2017-06-13 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2002074769A1 (fr) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane
WO2004055016A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
WO2004054974A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
US20060205697A1 (en) * 2004-11-12 2006-09-14 Robinson Gary N Novel betulin derivatives, preparation thereof and use thereof
US20100190795A1 (en) * 2006-06-07 2010-07-29 Valtion Teknillinen Tutkimuskeskus Betulin derived compounds useful as antiprotozoal agents
WO2009082818A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
WO2010053817A1 (en) * 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US20110218204A1 (en) * 2009-07-14 2011-09-08 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of novel betulinic acid derivatives
WO2011010038A1 (fr) 2009-07-20 2011-01-27 Institut Francais Textile Et Habillement Association de produits cationiques et anioniques naturels comme liant pour support textile
WO2011100308A1 (en) 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013091144A1 (en) 2011-12-21 2013-06-27 Glaxosmithkline Llc Propenoate derivatives of betulin

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts Properties, Selection, and Use", 2002
"Larock's Comprehensive Organic Transformations", 1989, VCH PUBLISHERS INC.
"Organic Reactions", vol. 1-40, 1991, JOHN WILEY AND SONS
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
"Rodd's Chemistry of Carbon Compounds", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS
E L ELIEL: "Stereochemistry of Organic Compounds", 1994, WILEY
FIESER: "Fieser's Reagents for Organic Synthesis", vol. 1-15, 1991, JOHN WILEY AND SONS
JERRY MARCH: "March's Advanced Organic Chemistry. 4th ed.", 1992, JOHN WILEY AND SONS
KNAPP, D. ET AL., J. CLIN. MICROBIOL., vol. 49, no. 1, 2011, pages 201 - 208
See also references of EP2791103A4
T. W. GREENE; G. M. WUTS: "Protecting Groups in Organic Synthesis", 1999, WILEY

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064873B2 (en) 2011-12-16 2018-09-04 Glaxosmithkline Llc Compounds and compositions for treating HIV with derivatives of Betulin
EP2812343A4 (en) * 2012-02-08 2015-12-02 Jiangxi Qingfeng Pharmaceutical Inc Lupane triterpene derivatives and their pharmaceutical use
US9795619B2 (en) 2012-12-14 2017-10-24 Glaxosmithkline Llc Pharmaceutical compositions
JP2016503030A (ja) * 2012-12-14 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 医薬組成物
EP2931285A4 (en) * 2012-12-14 2016-06-01 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS
AU2013358897B2 (en) * 2012-12-14 2017-01-05 Glaxosmithkline Llc Pharmaceutical compositions
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US9868758B2 (en) 2014-06-30 2018-01-16 Hetero Labs Limited Betulinic proline imidazole derivatives as HIV inhibitors
WO2016046786A1 (en) 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
US10092523B2 (en) 2014-09-26 2018-10-09 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
JP2017537898A (ja) * 2014-11-14 2017-12-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド 拡張ベツリン酸類似体
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
CN107250151A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 扩展的桦木酸类似物
CN107250153A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 氧代羽扇豆烯衍生物
AU2015346314B2 (en) * 2014-11-14 2018-04-12 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
WO2016077572A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Extended betulinic acid analogs
US10533035B2 (en) 2015-02-09 2020-01-14 Hetero Labs Ltd. C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
WO2016178092A2 (en) 2015-02-09 2016-11-10 Hetero Research Foundation C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
US11034718B2 (en) 2015-02-09 2021-06-15 Hetero Labs Limited C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
WO2017017607A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CN108026140A (zh) * 2015-07-28 2018-05-11 葛兰素史克知识产权第二有限公司 用于预防或治疗hiv感染的白桦脂醇衍生物
CN108026139A (zh) * 2015-07-28 2018-05-11 葛兰素史克知识产权第二有限公司 用于预防或治疗hiv感染的白桦脂醇衍生物
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017051355A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019186342A1 (en) 2018-03-27 2019-10-03 Glaxosmithkline Intellectual Property (No.2) Limited Ionic liquid salts of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019207460A1 (en) 2018-04-24 2019-10-31 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
EP4321164A2 (en) 2018-04-24 2024-02-14 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
JO3387B1 (ar) 2019-03-13
PH12017501429A1 (en) 2019-02-27
US20160120878A1 (en) 2016-05-05
EP2791103B1 (en) 2017-08-02
PH12014501362B1 (en) 2014-09-22
AU2012352110B2 (en) 2016-05-12
CN107501383A (zh) 2017-12-22
CR20140301A (es) 2014-08-21
IL233081A (en) 2017-11-30
EP2791103A1 (en) 2014-10-22
ME02895B (me) 2018-04-20
MX360679B (es) 2018-11-13
PL2791103T3 (pl) 2018-02-28
ZA201404135B (en) 2019-04-24
US20170348324A1 (en) 2017-12-07
RS56373B1 (sr) 2017-12-29
CA2859030C (en) 2020-06-16
SG11201402707PA (en) 2014-09-26
TW201336862A (zh) 2013-09-16
EP3263580A1 (en) 2018-01-03
HUE034877T2 (hu) 2018-03-28
PH12014501362A1 (en) 2014-09-22
JP2015501845A (ja) 2015-01-19
US10064873B2 (en) 2018-09-04
US20170252356A1 (en) 2017-09-07
AR089285A1 (es) 2014-08-13
JP2018065867A (ja) 2018-04-26
EP2791103A4 (en) 2015-05-06
IL233081A0 (en) 2014-08-03
KR101953869B1 (ko) 2019-03-04
ES2644578T3 (es) 2017-11-29
US9102685B2 (en) 2015-08-11
EA027363B1 (ru) 2017-07-31
PE20141788A1 (es) 2014-12-10
BR112014014769A2 (pt) 2017-06-13
MA35833B1 (fr) 2014-12-01
CN105008322B (zh) 2017-09-26
DOP2014000121A (es) 2014-07-31
UY34523A (es) 2013-07-31
KR20140104037A (ko) 2014-08-27
TW201730202A (zh) 2017-09-01
US20140357643A1 (en) 2014-12-04
NZ625516A (en) 2016-01-29
PT2791103T (pt) 2017-11-09
CA2859030A1 (en) 2013-06-20
CN105008322A (zh) 2015-10-28
PH12017501426A1 (en) 2020-07-13
MX2014007280A (es) 2014-07-22
CO6970600A2 (es) 2014-06-13
CY1119422T1 (el) 2018-03-07
LT2791103T (lt) 2017-10-25
US20130184263A1 (en) 2013-07-18
HRP20171512T1 (hr) 2017-11-17
CL2014001585A1 (es) 2015-02-27
US20150218142A1 (en) 2015-08-06
AU2012352110A1 (en) 2014-07-10
SI2791103T1 (sl) 2017-11-30
UA116978C2 (uk) 2018-06-11
EA201490919A1 (ru) 2014-11-28
DK2791103T3 (en) 2017-10-02
JP6300730B2 (ja) 2018-03-28
HK1210180A1 (en) 2016-04-15
TWI583696B (zh) 2017-05-21
EA201790923A1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
US10064873B2 (en) Compounds and compositions for treating HIV with derivatives of Betulin
EP2791102B1 (en) Propenoate derivatives of betulin
WO2013020246A1 (en) Methylene derivatives of betulin
CN104844679B (zh) 白桦脂醇的衍生物
NZ625516B2 (en) Derivatives of betulin
CA2993758A1 (en) Betuin derivatives for preventing or treating hiv infections
AU2016298669A1 (en) Betuin derivatives for preventing or treating HIV infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12017501429

Country of ref document: PH

Ref document number: 12017501426

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12857774

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 14117726

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 201490919

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2859030

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 233081

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2014547462

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014001585

Country of ref document: CL

Ref document number: 14365802

Country of ref document: US

Ref document number: 000975-2014

Country of ref document: PE

Ref document number: MX/A/2014/007280

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012857774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2014-000301

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: IDP00201404011

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2012352110

Country of ref document: AU

Date of ref document: 20121214

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201406100

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20147019864

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014014769

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014014769

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140616

ENP Entry into the national phase

Ref document number: 112014014769

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140616